All In Biotech

NDA 017849 · Ani Pharms

Brethine

Terbutaline Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Apr 8, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

May 17, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

52

22 Phase 3, 4 recruiting

FAERS reports

1,839

1,762 serious, 169 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: TOCOYSIS Oral terbutaline sulfate has not been approved for and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. During pregnancy, serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [See Contraindications-Tocolysis ]

What it is approved for

From the label in effect Nov 15, 2019.

INDICATIONS AND USAGE Terbutaline Sulfate Tablets USP are indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 17, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • BRETHINE · TERBUTALINE SULFATE 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
  • BRETHINE · TERBUTALINE SULFATE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Terbutaline" as an intervention, any sponsor and status, largest first.

All 52 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea426
  • asthma380
  • wheezing258
  • pneumonia209
  • cough206
  • drug ineffective153
  • fatigue148
  • loss of personal independence in daily activities142
  • therapeutic product effect incomplete124
  • sleep disorder due to a general medical condition120
  • nasopharyngitis112
  • malaise108

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200463
200557
200651
200783
200877
200981
201077
201159
201218
201331
201428
201532
201625
201749
201854
2019111
2020149
2021183
2022189
2023138
2024119
202587
202678

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 896 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.